The global antiviral drug resistance market is expected to reach US$ 4,573.24 Mn in 2027 from US$ 2,572.26 Mn in 2018. The Antiviral drug resistance market is estimated to grow with a CAGR of 6.8% from 2019-2027.
The market is driven by factors such as, rise in the incidences of hepatitis diseases and increasing prevalence of HIV/AIDS. However, the availability of alternative approaches may limit the growth of the market to a certain extent.
Get Sample PDF of this Report @ https://www.theinsightpartners.com/sample/TIPRE00006395/
Antiviral drug resistance refers to decreased susceptibility towards a drug which occurs due to changes in viral genotypes. During instances of antiviral resistance, the drugs have either lost their effectiveness or have been diminished against the virus to be targeted. Antiviral drug resistance is a rising concern among the immune-compromised patients.
Some of the major primary and secondary sources included in the report include, National Cancer Institute, National AIDS Research Institute, International Diabetes Federation, Centers for Disease Control and Prevention, and Food and Drug Administration, among others.
Viruses are the tinier germs that can cause several infectious diseases such as flu, common cold, and warts. Viruses can also cause severe illnesses, including smallpox, HIV/AIDS, and Ebola. Viruses reproduce inside cells and able to enter into any living, healthy cells and multiply and produce other viruses like themselves. Different viruses attack specific cells in the body such as liver, brain, skin, blood and also reproductive, respiratory, and gastrointestinal systems.
Ask For Discount @ https://www.theinsightpartners.com/discount/TIPRE00006395/
The prevalence of virus infections such as hepatitis has increased during recent years across the globe. Hepatitis causes liver damage and inflammation that can also damage other organs. It is a major global health problem that can cause chronic infection and also upsurge the higher risk of death from cirrhosis and liver cancer. Hepatitis can be categorized as hepatitis A, B, C, D, and E that spread through different causes. According to the WHO (World Health Organization), the prevalence of Hepatitis B is the highest in the African and Western Pacific Region, where 6.1% and 6.2% of the adult population is infected respectively.
In spite of stringent quality control measures and advanced tools, a limited number of antiviral drugs are getting approved for human use. The mechanism of action of the antiviral drugs can differ, strengthening the immune response to the viral infection and ranging from targeting viral proteins to cellular proteins. Apart from antiviral drugs, some alternative approaches are used for the treatment of viral diseases. These approaches include antisense oligonucleotides, aptamers, immunomodulators, vaccines, and ribozymes. The antisense nucleotide method comprises targeting specific nucleotides rather than proteins. Besides, oligonucleic acid or peptide molecules that bind to a particular target molecule is known as Aptamer. The peptide aptamers are used to treat viral infections. The peptide aptamers are designed to restrict other protein interactions inside the cells.
Purchase this Report @ https://www.theinsightpartners.com/buy/TIPRE00006395/
Global antiviral drug resistance were segmented by product, disease indication, technology, and end user. The product segment was categorized as kits & reagents and instruments. On the basis of the disease indication, the market is segmented as Human Immunodeficiency Virus [HIV], Hepatitis and Cytomegalovirus [CMV]. Similarly, based on technology, the market is fragmented as, immunodiagnostics, polymerase chain reaction [PCR], next generation sequencing [NGS], and other technologies. Based on end user, the antiviral drug resistance market is categorized as, hospitals & clinics, pathology or diagnostic laboratories and research institutes.
TABLE OF CONTENTS
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Global Antiviral Drug Resistance Market – By Product
1.3.2 Global Antiviral Drug Resistance Market – By Disease Indication
1.3.3 Global Antiviral Drug Resistance Market – By Technology
1.3.4 Global Antiviral Drug Resistance Market – By End User
1.3.5 Global Antiviral Drug Resistance Market – By Geography
2. Global Antiviral Drug Resistance Market – Key Takeaways
3. Research Methodology
3.2 Secondary Research
3.3 Primary Research
4. Global Antiviral Drug Resistance Market Landscape
4.2 PEST Analysis
4.2.1 North America PEST Analysis
4.2.2 Europe PEST Analysis
4.2.3 Asia Pacific PEST Analysis
4.2.4 Middle East & Africa PEST Analysis
4.2.5 South & Central America PEST Analysis
4.3 Expert Opinion
4.4 Cost of Test, By Test Type
4.5 Test Volume, By Region
5. Global Antiviral Drug Resistance Market – Key Industry Dynamics
5.1 Key Market Drivers
5.1.1 Rise in the Incidences of Hepatitis Diseases
5.1.2 Increasing Prevalence of HIV/AIDS
5.2 Key Market Restraints
5.2.1 Alternative Approaches
5.3 Key Market Opportunities
5.3.1 Increasing Healthcare Expenditures in Emerging Markets
5.4 Future Trends
5.4.1 Demand For Higher Quality Products
5.5 Impact Analysis
Email: [email protected]
This post was originally published on The Picayune Current